NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-OH-23-005 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit meritorious applications from universities with graduate degree programs in both mining and explosives engineering to develop and conduct research initiatives in automation, robotics, and intelligent mining systems to improve workplace safety and health in U.S. mining operations and to build on NIOSH's work to address Congress mandates in the Consolidated Appropriations Act of 2023. This research will contribute to the goal of eliminating mining fatalities within the next two decades.
Notice NOT-GM-23-033 from the NIH Guide for Grants and Contracts
Notice NOT-RM-23-005 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-080 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-044 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-220 from the NIH Guide for Grants and Contracts
Notice NOT-HG-23-021 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-087 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-028 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-091 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-032 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-076 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-031 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-089 from the NIH Guide for Grants and Contracts
Notice NOT-ES-23-006 from the NIH Guide for Grants and Contracts
Notice NOT-LM-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-001 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-23-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to: (1) support the maintenance and resource infrastructure enrichment for existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations to be inclusive of under-resourced minority-serving institutions and under-represented minority researchers.The ultimate goal is to maintain and maximize NIEHS cohort investments within the environmental epidemiology community by improving data collection on under-represented populations in environmental health studies, strengthening workforce diversity and promoting greater scientific collaboration.
Notice NOT-OD-23-075 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-24-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.